Medirom Healthcare Technologies Stock Net Income
| MRM Stock | USD 1.09 0.03 2.68% |
Medirom Healthcare Technologies fundamentals help investors to digest information that contributes to Medirom Healthcare's financial success or failures. It also enables traders to predict the movement of Medirom Stock. The fundamental analysis module provides a way to measure Medirom Healthcare's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medirom Healthcare stock.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 115 M | 120.8 M | |
| Net Loss | -891.7 M | -847.1 M | |
| Net Income | 115 M | 120.8 M | |
| Net Income Per Share | 22.27 | 23.38 | |
| Net Income Per E B T | 5.58 | 5.86 |
Medirom | Net Income |
Medirom Healthcare Technologies Company Net Income Analysis
Medirom Healthcare's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Medirom Healthcare Net Income | 115.05 M |
Most of Medirom Healthcare's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medirom Healthcare Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Medirom Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Medirom Healthcare is extremely important. It helps to project a fair market value of Medirom Stock properly, considering its historical fundamentals such as Net Income. Since Medirom Healthcare's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Medirom Healthcare's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Medirom Healthcare's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Medirom Healthcare Technologies reported net income of 115.05 M. This is 77.47% lower than that of the Health Care Providers & Services sector and 53.29% lower than that of the Health Care industry. The net income for all United States stocks is 79.85% higher than that of the company.
Medirom Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medirom Healthcare's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medirom Healthcare could also be used in its relative valuation, which is a method of valuing Medirom Healthcare by comparing valuation metrics of similar companies.Medirom Healthcare is currently under evaluation in net income category among its peers.
Medirom Healthcare Current Valuation Drivers
We derive many important indicators used in calculating different scores of Medirom Healthcare from analyzing Medirom Healthcare's financial statements. These drivers represent accounts that assess Medirom Healthcare's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Medirom Healthcare's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 7.0B | 6.0B | 3.4B | 3.2B | 4.2B | 5.8B | |
| Enterprise Value | 8.2B | 6.4B | 5.1B | 5.1B | 7.7B | 7.7B |
Medirom Healthcare Institutional Holders
Institutional Holdings refers to the ownership stake in Medirom Healthcare that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Medirom Healthcare's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Medirom Healthcare's value.| Shares | Ubs Group Ag | 2024-09-30 | 18 K | Bank Of America Corp | 2024-09-30 | 25.0 |
Medirom Fundamentals
| Return On Equity | 1.47 | ||||
| Return On Asset | -0.036 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 30.59 M | ||||
| Shares Outstanding | 7.9 M | ||||
| Shares Owned By Insiders | 40.37 % | ||||
| Number Of Shares Shorted | 107.56 K | ||||
| Price To Book | 13.24 X | ||||
| Price To Sales | 0 X | ||||
| Revenue | 6.83 B | ||||
| Gross Profit | 1.42 B | ||||
| EBITDA | 310.08 M | ||||
| Net Income | 115.05 M | ||||
| Cash And Equivalents | 354.95 M | ||||
| Cash Per Share | 72.70 X | ||||
| Total Debt | 3.65 B | ||||
| Current Ratio | 0.36 X | ||||
| Book Value Per Share | 43.19 X | ||||
| Cash Flow From Operations | (631.74 M) | ||||
| Short Ratio | 0.71 X | ||||
| Earnings Per Share | (0.15) X | ||||
| Number Of Employees | 390 | ||||
| Beta | 0.009 | ||||
| Market Capitalization | 8.81 M | ||||
| Total Asset | 6.85 B | ||||
| Retained Earnings | 80.28 M | ||||
| Working Capital | (1.8 B) | ||||
| Net Asset | 6.85 B |
About Medirom Healthcare Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medirom Healthcare Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medirom Healthcare using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medirom Healthcare Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Medirom Healthcare Piotroski F Score and Medirom Healthcare Altman Z Score analysis. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medirom Healthcare. If investors know Medirom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medirom Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.582 | Earnings Share (0.15) | Revenue Per Share 1.4 K | Quarterly Revenue Growth (0.06) | Return On Assets (0.04) |
The market value of Medirom Healthcare is measured differently than its book value, which is the value of Medirom that is recorded on the company's balance sheet. Investors also form their own opinion of Medirom Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Medirom Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medirom Healthcare's market value can be influenced by many factors that don't directly affect Medirom Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medirom Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Medirom Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medirom Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.